Orchids
-
{
- All
- News
- Videos
- Web Stories
-
MahaRERA Tribunal Quashes Turf View Deregistration; DB Realty-Linked Promoters Fined 2% Of Project Cost
The MahaRERA Tribunal restored Turf View's residential registration, ruling that invalid buyer consent was used to pursue a commercial redevelopment by DB Realty-linked promoters.
-
Orchid Pharma Shares Zooms 10% On Russian Market Entry With Antibiotic Licensing Deal
With the signing of the deal, shares of Orchid Pharma surged 10% in trade to hit an intraday high of Rs 1,047, nearing the 52-week high mark of Rs 1,094 apiece on the NSE. The triple-digit PE pharma stock traded above the Rs 1,000-mark with the surge in the intraday share price, defying the Nifty 50 benchmark index.
-
Which State In India Is Called The Land Of Orchids? And, The Best Way To Explore It
Arunachal Pradesh is more than just the Land of Orchids. It is a place filled with stories, traditions and natural beauty.
-
IndiGo's 10% Cut In Flight Operations To Hit Tourism-Heavy Regions In 2026: Royal Orchid Hotels CFO
The IndiGo crisis underlines the need for diversified travel options in India's hospitality sector, said Amit Jaiswal, CFO, Royal Orchid Hotels.
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
Orchid Pharma Q2 Review: Systematix Maintains 'Buy' Despite Earnings Collapse — Here's Why
Orchid Pharma's valuation stays rich at 67x FY26 P/E despite negative earnings trajectory, adds Systematix.
-
Royal Orchid Hotels Sets 25% RoCE Target In Five Years As Focus Shifts On Cost Control
Royal Orchid Hotels is also expecting strong impact from the recent GST revision
-
Arunachal Pradesh To Be Named India's Orchid Capital In New Tourism Push
With its commitment to sustainability and cultural preservation, Arunachal Pradesh is steadily emerging as a must-visit destination in India.
-
'Buy' Sun Pharma, Cipla; 'Hold' Lupin, Indoco Among Other Pharma Stocks, Says Systematix Ahead Of Q4 Results
Systematix expects select companies in the US to benefit from the ramp up in generic Revlimid like Zydus Life and Sun Pharmaceuticals.
-
Hotels Q4 Results Preview: RevPAR Growth Sustainability Key, Says Dolat Capital; Lemon Tree Among Top Picks
Dolat Capital finds Mahindra Holidays and Lemon Tree to be well-positioned in the hospitality space, offering risk-reward over the medium term, hence remains top pick.
-
Orchid Pharma Facility Gets Seven Observations After FDA Inspection
The Alathur API facility has also secured the renewal of its EU Good Manufacturing Practice certificate following a successful inspection.
-
Orchid Pharma Q3 Results Review: Systematix Recommends 'Buy' On The Stock — Here's Why
Orchid Pharma is also looking to tap into generic ceftazidime / avibactam market in U.S. and EU and is working on a non-infringing route to gain an early entry, adds the brokerage.
-
Orchid Pharma Q3 Results Review: Systematix Recommends 'Buy' On The Stock — Here's Why
Orchid Pharma is also looking to tap into generic ceftazidime / avibactam market in U.S. and EU and is working on a non-infringing route to gain an early entry, adds the brokerage.
-
Royal Orchid Hotels Expects Upto 20% Jump In Average Room Rents In FY26, FY27
Royal Orchid Hotels' average room rents in the first half of fiscal 2025 went up to Rs 5,100, as compared to Rs 4,700 in the year-ago period, the company's CEO Amit Jaiswal said.
-
Orchid AMS To Achieve Rs 250 Crore Turnover Only By FY28, Says CEO Rajnish Rohatgi
As a result of the product launch delays, the CEO admitted that the financials of Orchid AMS will be affected in FY26.
-
MahaRERA Tribunal Quashes Turf View Deregistration; DB Realty-Linked Promoters Fined 2% Of Project Cost
The MahaRERA Tribunal restored Turf View's residential registration, ruling that invalid buyer consent was used to pursue a commercial redevelopment by DB Realty-linked promoters.
-
Orchid Pharma Shares Zooms 10% On Russian Market Entry With Antibiotic Licensing Deal
With the signing of the deal, shares of Orchid Pharma surged 10% in trade to hit an intraday high of Rs 1,047, nearing the 52-week high mark of Rs 1,094 apiece on the NSE. The triple-digit PE pharma stock traded above the Rs 1,000-mark with the surge in the intraday share price, defying the Nifty 50 benchmark index.
-
Which State In India Is Called The Land Of Orchids? And, The Best Way To Explore It
Arunachal Pradesh is more than just the Land of Orchids. It is a place filled with stories, traditions and natural beauty.
-
IndiGo's 10% Cut In Flight Operations To Hit Tourism-Heavy Regions In 2026: Royal Orchid Hotels CFO
The IndiGo crisis underlines the need for diversified travel options in India's hospitality sector, said Amit Jaiswal, CFO, Royal Orchid Hotels.
-
Stocks To Buy: Sun Pharma, Cipla, Rainbow Among Systematix Top Picks In Healthcare Space Post Q2 Results
Systematix’s top picks for the sector include Sun Pharma, Cipla, Ajanta Pharma among others - Check full list.
-
Orchid Pharma Q2 Review: Systematix Maintains 'Buy' Despite Earnings Collapse — Here's Why
Orchid Pharma's valuation stays rich at 67x FY26 P/E despite negative earnings trajectory, adds Systematix.
-
Royal Orchid Hotels Sets 25% RoCE Target In Five Years As Focus Shifts On Cost Control
Royal Orchid Hotels is also expecting strong impact from the recent GST revision
-
Arunachal Pradesh To Be Named India's Orchid Capital In New Tourism Push
With its commitment to sustainability and cultural preservation, Arunachal Pradesh is steadily emerging as a must-visit destination in India.
-
'Buy' Sun Pharma, Cipla; 'Hold' Lupin, Indoco Among Other Pharma Stocks, Says Systematix Ahead Of Q4 Results
Systematix expects select companies in the US to benefit from the ramp up in generic Revlimid like Zydus Life and Sun Pharmaceuticals.
-
Hotels Q4 Results Preview: RevPAR Growth Sustainability Key, Says Dolat Capital; Lemon Tree Among Top Picks
Dolat Capital finds Mahindra Holidays and Lemon Tree to be well-positioned in the hospitality space, offering risk-reward over the medium term, hence remains top pick.
-
Orchid Pharma Facility Gets Seven Observations After FDA Inspection
The Alathur API facility has also secured the renewal of its EU Good Manufacturing Practice certificate following a successful inspection.
-
Orchid Pharma Q3 Results Review: Systematix Recommends 'Buy' On The Stock — Here's Why
Orchid Pharma is also looking to tap into generic ceftazidime / avibactam market in U.S. and EU and is working on a non-infringing route to gain an early entry, adds the brokerage.
-
Orchid Pharma Q3 Results Review: Systematix Recommends 'Buy' On The Stock — Here's Why
Orchid Pharma is also looking to tap into generic ceftazidime / avibactam market in U.S. and EU and is working on a non-infringing route to gain an early entry, adds the brokerage.
-
Royal Orchid Hotels Expects Upto 20% Jump In Average Room Rents In FY26, FY27
Royal Orchid Hotels' average room rents in the first half of fiscal 2025 went up to Rs 5,100, as compared to Rs 4,700 in the year-ago period, the company's CEO Amit Jaiswal said.
-
Orchid AMS To Achieve Rs 250 Crore Turnover Only By FY28, Says CEO Rajnish Rohatgi
As a result of the product launch delays, the CEO admitted that the financials of Orchid AMS will be affected in FY26.
